- Home
- RRC vs LNTH Comparison
RRC vs LNTH Comparison
Compare RRC & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RRC | LNTH |
|---|---|---|
| Founded | 1976 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 4.4B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RRC | LNTH |
|---|---|---|
| Price | $35.54 | $65.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 6 |
| Target Price | $41.94 | ★ $77.33 |
| AVG Volume (30 Days) | ★ 3.3M | 1.1M |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 19.84 | N/A |
| EPS | 2.38 | ★ 2.39 |
| Revenue | ★ $2,891,506,000.00 | $1,525,933,000.00 |
| Revenue This Year | $28.16 | $0.01 |
| Revenue Next Year | $11.34 | $1.24 |
| P/E Ratio | ★ $14.50 | $27.23 |
| Revenue Growth | ★ 24.57 | 1.95 |
| 52 Week Low | $30.32 | $47.25 |
| 52 Week High | $43.50 | $111.29 |
Technical Indicators
Market Signals| Indicator | RRC | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 66.32 |
| Support Level | $33.80 | $60.15 |
| Resistance Level | $40.88 | $67.40 |
| Average True Range (ATR) | 1.12 | 2.04 |
| MACD | -0.47 | 0.52 |
| Stochastic Oscillator | 24.51 | 77.40 |
Price Performance
Historical ComparisonAbout RRC Range Resources Corporation
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.18 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.